• Publications
  • Influence
Global Epidemiology of Hepatitis B Virus
The burden of hepatitis B virus (HBV) disease and efforts to control infection will determine the future size of the population requiring treatment of HBV infection. To quantify the currentExpand
  • 578
  • 41
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
BACKGROUND Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated theExpand
  • 819
  • 31
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study
Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited, with the currently approved all‐oral regimens requiring 24‐week treatment and the addition of ribavirinExpand
  • 554
  • 28
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been suggested to be of benefit based on open label clinicalExpand
  • 616
  • 18
Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
This guideline has been approved by the American Association for the Study of Liver Diseases (AASLD) and represents the position of the association.
  • 474
  • 18
ACG Clinical Guideline: Primary Sclerosing Cholangitis
Primary sclerosing cholangitis is a chronic cholestatic liver disease that can shorten life and may require liver transplantation. The cause is unknown, although it is commonly associated withExpand
  • 216
  • 18
Prognostic factors in acute pancreatitis.
The assessment of the severity of acute pancreatitis (AP) is a critical early step in its management, as severity of AP predicts prognosis. A range of options are available for assessment of severityExpand
  • 273
  • 18
Ursodiol Use Is Associated with Lower Prevalence of Colonic Neoplasia in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis
Patients with ulcerative colitis have an increased risk for colorectal neoplasia; this risk approaches 0.5% to 1% per year of disease. The extent and duration of colitis, as well as age at onset ofExpand
  • 419
  • 15
High-Dose Ursodeoxycholic Acid Is Associated With the Development of Colorectal Neoplasia in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis
OBJECTIVES:Some studies have suggested that ursodeoxycholic acid (UDCA) may have a chemopreventive effect on the development of colorectal neoplasia in patients with ulcerative colitis (UC) andExpand
  • 189
  • 14
Etiology and outcome for 295 patients with acute liver failure in the United States.
Little information is available on acute liver failure (ALF) in the United States. We gathered demographic data retrospectively for a 2-year period from July 1994 to June 1996 on all cases of ALFExpand
  • 344
  • 13